FY10/11FY10/11

FY 2010FY 2010--2011 2011

Annual Results PresentationAnnual Results Presentation

(12 Months Ended March 31(12 Months Ended March 31stst, 2011), 2011)

Media Presentation Jun 2011

Data and information contained in this presentation is provided for informational purposes only. GoldenMeditech Holdings Limited takes no liabilities for any errors or delays in the content, or for any actionstaken in reliance thereon.

This presentation and subsequent discussions may contain forward-looking statements that are basedon the current beliefs, assumptions, expectations, estimates, and projections of the management ofGolden Meditech Holdings Limited about its businesses and the industries and markets in which it

Disclaimer

2

Golden Meditech Holdings Limited about its businesses and the industries and markets in which itoperates. These forward-looking statements include, without limitation, statements relating to revenues,earnings and stock performance. The words “believe”, “intend”, “expect”, “anticipate”, “project”,“estimate”, “predict” and similar expressions are also intended to identify the forward-looking statements.These statements are not guarantees of future performance and are subject to various risks anduncertainties, including, but not limited to, changes in legal, financial and regulatory frameworks, actualdemand, exchange rate fluctuations, market shares, competition, environmental risks, internationaleconomic and financial market conditions, project approval, cost estimates and other risks, which arebeyond the control of Golden Meditech Holdings Limited and are difficult to predict. Consequently, futurefinancial results could differ materially from those expressed or forecasted in the forward-lookingstatements.

• Company Profile

• FY10/11 Highlights

• Review of Operations

• Recent Updates on Hospital Management Business

Agenda

• Recent Updates on Hospital Management Business

• Q&A

3

Company Profile

The Healthcare Services Segment

•First foreign hospital management company with nationwide license in China

•Owner of two Daopei Hospitals, the largest haematology hospitals in China

•Acquiring Shanghai East International Medical Centre, premium hospital in June 2011

•Acquiring a 500-bed hospital facility in Beijing and commence operation by 2012

•First ever medical insurance information management BPO in China

4

•First ever medical insurance information management BPO in China

•Founded China’s first and largest cord blood banking operator, China Cord Blood Corporation

The Medical Devices Segment

•Beijing Jingjing Medical Equipment Co., Ltd. (“BJJJ”) - leading medical devices manufacturer in

China

•Joint-Venture with global leader in blood-related technology, Fenwal Inc.

•Shareholder of China’s leading medical equipment distributor in China National Medical

Equipment Industry Corporation (“CMIC”)

Golden Meditech (801.HK; 910801.TW)

Medical Devices

Segment

Beijing Jingjing Medical

Healthcare Services

Segment

China Cord Blood GM-Medicare

Strategic Investment

FunTalk China Holdings

Business Structure

Beijing Jingjing Medical

Equipment Co., Ltd.

Joint venture with

Fenwal Inc.

China National Medical Equipment Industry

Corporation

China Cord Blood

Corporation

(NYSE: CO)

GM Hospital Group

Beijing DaopeiHospital

Shanghai DaopeiHospital

Shanghai East International Medical

Center

GM-Medicare Management (China) Co.,

Ltd.

FunTalk China Holdings

Limited (FTLK.NASDAQ)

5

NB: Entities highlighted in BLUE represents publicly listed entities.

FY2010/2011 Highlights• Turnover �14.9% to HK$328mm, solid growth from all business segments

• Profit from operations impressive growth �61.9% to HK$220mm (+Proforma operating income�15.2% to HK$216mm )

• Profit attributable to shareholders �194.8% to HK$343mm (*Adjusted �40.4% to HK$307mm)

• Earnings per share (basic) �176% to HK19.9cents

• Gross margin remain steady at 58%;

• Healthy cash level – cash-on-hand stood at HK$771mm

6

+Proforma operating income includes profit from operations, contribution from associates and jointly controlled entities, excluding

exceptional items.

*Adjusted for non-cash, mark to-market, fair-value-change due to changes in the Company’s share price and value of outstanding CB

and warrants of GMHG and the Group

• Major progress and breakthrough in hospital management:

– To acquire Shanghai East International Medical Center

– To acquire new premise for Beijing Daopei hospital expansion in June 2011 - 5 fold of current capacity

• CCBC contributed HK$41.7mm to Group – secured new license for Zhejiang

• Launched China’s first medical insurance info management BPO, GM-Medicare, in April 2010

• Expanding medical devices capacity for impending growth, sign agreement for Fenwal JV

• Listed 90 mm units of Taiwan Depositary Receipts, equivalent to 180mm shares

FY10/11 Results SummaryHK$ ‘000 FY10/11 FY09/10 % Change

Turnover 328,066 285,467 14.9%

Gross Profit 188,734 172,644 9.3%

Profit from Operations 220,169 135,988 61.9%

Changes in Fair Value of CB and Warrants (Note 1) 36,009 (102,357) NA

Proforma Operating Profit (Note 2) 215,831 187,432 15.2%

Earnings before taxation 401,569 158,355 153.6%

7

Note 1: Non-cash, mark to-market, fair-value-change due to changes in the Company’s share price and value of outstanding CB

and Warrants of GMHG and the Group

Note 2: Proforma operating income includes profit from operations, contribution from associates and jointly controlled entities,

excluding exceptional items.

Note 3: Adjusted for non-cash, mark to-market, fair-value-change due to changes in the Company’s share price and value of

outstanding CB and warrants of GMHG and the Group

Earnings before taxation 401,569 158,355 153.6%

Profit Attributable to Shareholders 343,208 116,412 194.8%

Adjusted Profits Attributable to Shareholders (Note 3) 307,199 218,769 40.4%

EPS (Basic) – HK cents 19.9 7.2 176.4%

Strong Balance Sheet

HK$ ‘000 FY10/11 1H10/11

Total Assets 6,040,692 5,219,035

Total Asset Less Current Liabilities 5,718,161 5,027,728

Total Equity 4,256,354 3,752,771

• Cash and bank deposits amounted to

HK$771mm (2010: HK$826mm); total

interest bearing debt stood at

HK$667mm (2010 : HK$759mm)

• The Group is in a satisfactory financial

position with sufficient capital and

financial resources to meet future

8

Cash and bank balances 770,591 746,443

Gearing ratio 15.7% 27.5%

Total Assets Less Current Liabilities

(HK$ mm)

2,329 2,7613,991 3,985 4,473

5,7182,1052,722

3,553 3,5383,575

4,256

0

2,000

4,000

6,000

FY05/06 FY06/07 FY07/08 FY08/09 FY09/10 FY10/11

Total assets less current liability

Total Equity

financial resources to meet future

business development needs.

Highlights of Healthcare Services Segment

Healthcare Services

(HK$ ‘million)

63,942137,809

221,221296,526

393,068

051,763

80,412

200,000

400,000 Hospital Management

Cord Blood

CCBC separately listed –

deconsolidated with contribution

as affiliate

• Hospital Management Business reported impressive first full-year revenue since the Group

completed the acquisition of the hospital group in June 2009

• Group entered into agreement to acquire 56% of Shanghai East International Medical Center

for US$10mm in cash and shares. SEIMC boasts a strong reputation in municipal Shanghai

serving expatriate and high end hospital markets

• Beijing Daopei Hospital is also due for expansion with a new facility in Haidian District in

Beijing. New facility will host 500 beds over a floor area of 74,035 m2

9

63,942137,809

0

FY06/07 FY07/08 FY08/09 FY09/10 FY10/11

Cord Blood Banking

Strengthening Healthcare Services Segment

� First foreign company to have a nation-wide hospital management license, to provide

hospital management consultancy service and management outsourcing services

� Currently operates Daopei Hospitals - 2 largest privately-owned haematology hospitals in

China, in Beijing and Shanghai – with 100 beds each

Highlights of Service Business

China, in Beijing and Shanghai – with 100 beds each

� Announced expansion of Beijing Daopei Hospital in Beijing to 500 beds

� Acquired Shanghai East International Medical Center to break into profitable expat market

� Total number of beds including SEIMC and Daopei Hospitals will be close to 700 beds by

2012, more than 3 times current capacity

10

• CCBC (CO.US) posted impressive growth and contributed HK$41.7mm to the Group.

Upcoming exclusive license in Zhejiang will be a solid base for sustained, long-term growth

Highlights of Service Business

Upcoming exclusive license in Zhejiang will be a solid base for sustained, long-term growth

• The Group currently owns 39.5% of CCBC’s shares

• CCBC’s FY2011 results

– FY2011 revenue up 29.8% YOY to RMB339.5 mm

– Total accumulative subscribers reached 185,830

– Gross margin reached 77.2%, comparing to 74.9% Y-o-Y

– Operating income increased 27.4% to RMB123.8mm from RMB97.2mm

– Net income attributable to shareholders up 86.5% to RMB91.7mm

from RMB49.2mm

11

216,756 224,446 203,387 146,249 148,581

100,000

200,000

300,000

400,000

Medical Devices

Medical Accessories

Highlights of Medical Devices Segment

Medical Devices

(HK$ ‘000) Strategic Price Cut

Medical Accessories

5-year CARG=18%

50,427 58,892 73,15787,455 96,170

0

100,000

FY06/07 FY07/08 FY08/09 FY09/10 FY10/11

12

• Revenue up 5% to HK$244.8mm, mostly attributable to increase in device utilization

• Medical accessories sales accounted for 39% of the revenue as opposed to 37% in FY09/10

• Implementation of the MOH’s “Regulation Governing Hospital Standard Accreditation and

Administration” (医院标准认证管理规范) will allow hospital operators to initiate strategies to remedy

shortage in surgical blood

• Group completed definitive agreement with Fenwal Inc. for the formation of joint venture in China,

targeting blood collection and infusion products market in China.

• Group raised US$36.5 million in August 2010 to expand production capacity for medical devices and

exclusive medical accessories

Stable Revenue and Cashflow

5-year CARG=18%

Company Outlook

• Cord blood bank to further increase market penetration in Beijing and Guangdong, and future maiden contribution from its Zhejiang operation

• New hospital operation will contribute to Group immediately upon completion of acquisition

Healthcare Services Segment:

13

upon completion of acquisition

• GM-Medicare, new medical insurance claim processing BPO to capture significant unaddressed demands in a new industry in China

• New strategies to promote device sales to lower tier hospitals

• Drive for growth in accessories sales

• New products launch and innovations

Medical device segment:

14

Q & A

Investor Relations Department

Email: ir@goldenmeditech.com

15

Email: ir@goldenmeditech.com

Tel: +852 3605 8180

Website: www.goldenmeditech.com